Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

Python is a programming language, and it was first introduced in 1991. Did you know that you can run Python code in your browser without any additional tools? With the help of specialized websites, ...

Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decision that rejected its lead drug ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Replimune Group, Inc. before investing. In this article, we go over a few key ...

A $1.8 billion mistake could cost the South Carolina treasurer his job Ranking All-You-Can-Eat Chain Buffets From Worst To First 35-year-old was 29 months away from getting her $247,804 student debt ...